Results 11 to 20 of about 48,156 (193)

Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. [PDF]

PLoS ONE, 2012
Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy.
Diana Machado, Isabel Couto, João Perdigão, Liliana Rodrigues, Isabel Portugal, Pedro Baptista, Bruno Veigas, Leonard Amaral, Miguel Viveiros   +8 more
doaj   +1 more source

Poor Compliance Makes Treatment of Latent Tuberculosis Infection Unsatisfactory

Journal of Primary Care & Community Health, 2012
Objectives: The recommended treatment for latent tuberculosis infection is isoniazid for 9 months, but this regimen has a low completion rate. The authors wanted to compare treatment with isoniazid and treatment with isoniazid and rifampin in the typical
Panupong Larppanichpoonphol, Satish Bagdure, Hoda Mojazi Amiri, Kenneth Nugent   +3 more
doaj   +1 more source

Phenotypic low-level isoniazid resistance as a marker to predict ethionamide resistance in Mycobacterium tuberculosis

International Journal of Mycobacteriology, 2017
Background: Tuberculosis is one of the most prevalent diseases in Pakistan. Pakistan has the highest burden of MDR-TB in the Eastern Mediterranean region. Ethionamide is an anti-tuberculous drug frequently used to treat MDR-TB.
Salima Qamar, Joveria Q Farooqi, Kausar Jabeen, Rumina Hasan   +3 more
doaj   +1 more source

The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats

Brazilian Journal of Medical and Biological Research, 2021
It is known that the combined use of antibiotics, such as isoniazid and rifampicin, in the treatment of tuberculosis causes oxidative kidney damage. The aim of this study was to biochemically and histopathologically investigate the effect of lycopene on ...
F. Bedir, H. Kocaturk, O. Turangezli, E. Sener, S. Akyuz, F.B. Ozgeris, B. Dabanlioglu, H. Suleyman, D. Altuner, B. Suleyman   +9 more
doaj   +1 more source

Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

Molecules, 2022
Isoniazid and its metabolites are potentially associated with hepatotoxicity and treatment outcomes in patients who receive antituberculosis (TB) therapy.
Nguyen Ky Anh, Pham My Tung, Min Jung Kim, Nguyen Phuoc Long, Yong-Soon Cho, Dong-Hyun Kim, Jae-Gook Shin   +6 more
doaj   +1 more source

Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon

The Pan African Medical Journal, 2020
INTRODUCTION: It is unclear what the optimal treatment regimen for previously treated patients with rifampicin-susceptible isoniazid resistant tuberculosis should be. Conflicting evidence exists as to the effectiveness of the WHO standardized category II
Christopher Kuaban, Louise Daniele Ingrid Toukam, Melissa Sander   +2 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. [PDF]

PLoS ONE, 2011
Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability.To inform clinical trial design by ...
David P Holland, Gillian D Sanders, Carol D Hamilton, Jason E Stout   +3 more
doaj   +1 more source

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Emerging Infectious Diseases, 2006
In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation.
Maria Elvira Balcells, Sara L. Thomas, Peter Godfrey-Faussett, Alison D. Grant   +3 more
doaj   +1 more source

Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi

Frontiers in Public Health, 2020
Background: Pellagra is caused by niacin (vitamin B3) deficiency and manifested by a distinctive dermatitis. Isoniazid is critical for treating tuberculosis globally and is a component of most regimens to prevent tuberculosis. Isoniazid may contribute to
Scott A. Nabity, Kelvin Mponda, Steve Gutreuter, Diya Surie, Anne Williams, Anne Williams, Andrea J. Sharma, Elizabeth R. Schnaubelt, Rebekah E. Marshall, Hannah L. Kirking, Suzgo B. Zimba, Joram L. Sunguti, Laphiod Chisuwo, Mabvuto J. Chiwaula, Jesse F. Gregory, Robin da Silva, Michael Odo, Andreas Jahn, Thokozani Kalua, Rose Nyirenda, Belaineh Girma, James Mpunga, Nicole Buono, Alice Maida, Evelyn J. Kim, Laurence J. Gunde, Tigest F. Mekonnen, Andrew F. Auld, Adamson S. Muula, John E. Oeltmann   +29 more
doaj   +1 more source